🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Listen to our CSO, Arndt Schottelius giving a talk #PEGSEurope on the early clinical outcomes of the AFM13-NK cell combination trial on Nov 15th, at 9:30 CET in Barcelona. Find the agenda here bit.ly/3DexHqo or learn about our recent update here: bit.ly/3tu2ye0

Today, we announce our Q3 2022 financial results and provide a corporate update. Access our Investor's call at 8:30 a.m. EST / 14:30 CET with the following link: bit.ly/3g7AoCy - A replay will be available for 30 days. To the press release: bit.ly/3hC2u9b

Our CEO, Adi Hoess will be giving a talk at this year’s Jefferies Healthcare Conference in London. Join his presentation via our webcast bit.ly/3O1EyIG on Wednesday, November 16th, 2022, at 7:55 EST/ 13:55 CET. #JefferiesHealthcare

Affimed will be hosting an investor event on December 10th at 4 p.m. CST / 5 p.m. EST / 23:00 CET in conjunction with #ASH22 to provide an update on our AFM13 development strategy. Please find more information here: bit.ly/3XQ8snC

Today, we announced 2 important data sets: topline data from our monotherapy Phase 2 REDIRECT trial in r/r PTCL patients & data from our study with MD Anderson Cancer Center evaluating the combination of AFM13 with NK cells. More here:bit.ly/3haDXZf bit.ly/3PicLEf #ASH22

Today at #ASH22 we gave an update on our preclinical innate cell engager (ICE®) #AFM28, targeting CD123+ cells in diseases such as acute myeloid #leukemia. AFM28 can successfully destroy tumor cells! bit.ly/3VOLXhC #WhyWeFightCancer #AffimedProud #AFM13 #InnateImmunity

The French National Agency for the Safety of Medicines & Health Products has authorized a CTA for our innate cell engager (ICE®), #AFM28. This allows us to advance its clinical development to fight relapsed / refractory #AML, a severe blood cancer: bit.ly/3WuVsTa

Today we announced a regulatory update for #AFM13 & reported on corporate progress. Read more here bit.ly/3VSCaWR. #AFM13 #InnateImmunity #ImmunoOncology

Join our CEO Adi Hoess for a fireside chat with Daina Greybosch, Ph.D., at this year's SVB Securities 2023 Global Biopharma Conference at 2:20 p.m. EST / 8:20 p.m. CET on Tuesday, February 14, 2023. To the webcast: bit.ly/3K3dAAl

Thank you Cormac Sheridan for taking the time to speak with our CMO, Dr. Andreas Harstrick, about Affimed's exciting data and the synergistic potential that ICE® molecules bring to the NK cell space. Read the article in Nature Biotechnology here: go.nature.com/3k7vNSD

Our CEO, Adi Hoess will participate in a fireside chat at the H.C. Wainwright & Co. Cell Therapy Conference today. Join our webcast bit.ly/3IINTEe at 8:30 a.m. EST / 14:30 CET to learn more about Affimed’s approach to fighting cancer.

Join us at this year’s Annual Meeting of the AACR in Orlando, Florida! We will host an oral presentation on results from our REDIRECT study and a poster presentation on the potential of AFM13 to induce effective ADCC. To the PR: bit.ly/3la19c6 #ImmunoOncology

Today at 8:30 a.m. EDT / 13:30 CET, we discuss our full year 2022 results and corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website. Full PR: bitly.ws/BYQN

We are pleased to announce that we have dosed the first patient in our first-in-human study investigating AFM28 in patients with relapsed/refractory CD123-positive Acute Myeloid Leukemia (AML). Read the full press release here: bitly.ws/CgZS

Affimed is pleased to announce two abstracts at EHA2023, the Annual Meeting of the European Hematology Association. Read more here bitly.ws/EpkQ #immunooncology #AFM13 #AFM28 #EHA2023

Affimed will be hosting an investor event June 3, 2023, at 6:00 PM CDT/ 7:00 PM EDT to review AFM24 monotherapy data and provide a strategic update on the program going forward. Webcast: bit.ly/43ACvls Dial in: bit.ly/45GHN0s #AFMD #AFM24 #InnateImmunity

Today Affimed provided details on the AFM24-101 monotherapy study in NSCLC at ASCO 2023 and provides a strategic update on the AFM24 development plan. For further details, see the full press release at: bit.ly/3WQ1bUX. #AFMD #AFM24 #ImmunoOncology

Today at 8:30 a.m. EDT / 14:30 CET, we discuss our Q2 2023 results and corporate update in a conference call. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at bit.ly/3Qz1x0V #AFMD

Today Affimed announced that it has received FDA Fast Track Designation for AFM13 combined w/ AB-101 for the treatment of patients with R/R Hodgkin lymphoma which will be investigated in the LuminICE-203 study (NCT05883449). Press release: bit.ly/3PfDqlB #Affimed

We are thrilled to announce Shawn M. Leland, Pharm D, RPh is Affimed's new CEO. Shawn has a proven track record in advancing cutting-edge oncology assets, securing significant capital, and negotiating global licensing agreements. Read more here: bit.ly/3Tdpv2k #AFMD